RxDoctor Payments DataLook up a doctor →

Naveed Ahmed, MD

Neurology · Pikeville, KYNPI 1508946070

Payments from drug & device makers

$226,005in general payments, 2019–2025

Across 754 payments — averaging $299.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$81K
  • AbbVie$40K
  • Biohaven Pharmaceuticals, Inc.$31K
  • Biogen$28K
  • Biohaven Pharmaceutical Holding Company Ltd.$18K
  • Janssen Research & Development, LLC$13K
  • plus $16K from 48 others

What the payments were for

  • Consulting fees$6,0233%
  • Speaking & faculty fees$184,50086%
  • Travel & lodging$11,3055%
  • Food & beverage$12,4496%
  • Education$2740%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$226,005 in reported general payments places this provider in the 90th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$83,514
Medicare patients
605
Services billed
1,041

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4620$166,144
UbrelvyUbrogepant92$114,941
Nurtec OdtRimegepant Sulfate80$84,917
QuliptaAtogepant41$43,229
Emgality PenGalcanezumab-Gnlm55$37,233
Ajovy AutoinjectorFremanezumab-Vfrm22$15,697
BriviactBrivaracetam11$13,214
Aimovig AutoinjectorErenumab-Aooe16$12,928
Pregabalin510$7,721
Tegretol XrCarbamazepine11$6,267
Levetiracetam287$3,568
Primidone234$3,041
Lidocaine19$2,673
Carbidopa-LevodopaCarbidopa/Levodopa110$2,140
Carbamazepine ErCarbamazepine30$1,903

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$14$166,14420 claims
AbbVieUbrelvy, Qulipta$39,796$158,169133 claims
PfizerNurtec Odt$135$84,91780 claims
UCB, Inc.Briviact$883$13,21411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 210 neurology providers in Kentucky.

Other neurology in Pikeville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →